Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Innate Immune Responses in COPD
NCT00826163Phase 3Completed
- Sponsor
- Mahidol University
- Start
- Jan 2009
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of budesonide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Mahidol University. Primary endpoints: Sputum Interleukin-8 at 2 weeks and Sputum Interleukin-17 at 2 weeks. Started Jan 2009; status: completed.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00826163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00826163.